Endocrine Connections for Special Issue on “Vitamin D and UV Light”

Historical Aspects of Vitamin D

Glenville Jones
Craine Distinguished Professor of Biochemistry
Department of Biomedical and Molecular Sciences
Queen’s University, Kingston. Ontario. Canada K7L 3N6
Email: gj1@queensu.ca

Short Title: History of Vitamin D

Keywords: VITAMIN D
VITAMIN D METABOLISM
RICKETS & OSTEOMALACIA
CALCIUM & PHOSPHATE HOMEOSTASIS
VITAMIN D ANALOGS
VITAMIN D FUNCTION
7-DEHYDROCHOLESTEROL
UV LIGHT

Word Count: Text: 4028 words; With 102 references and figure legends: 7017 words.
Abstract
Vitamin D has many physiological functions including upregulation of intestinal calcium and phosphate absorption, mobilization of bone resorption, renal reabsorption of calcium as well as actions on a variety of pleiotropic functions. It is believed that many of the hormonal effects of vitamin D involve a 1,25-dihydroxyvitamin D$_3$-vitamin D receptor (VDR)-mediated transcriptional mechanism involving binding to the cellular chromatin and regulating hundreds of genes in many tissues. This comprehensive historical review provides a unique perspective of the many steps of the discovery of vitamin D & its deficiency disease, rickets, stretching from 1650 until the present. The overview is divided into four distinct historical phases which cover the major developments in the field and in the process highlighting the: a) first recognition of rickets or vitamin D deficiency; b) discovery of the nutritional factor, vitamin D and its chemical structure; c) elucidation of vitamin D metabolites including the hormonal form, 1,25-dihydroxyvitamin D$_3$; d) delineation of the vitamin D cellular machinery, functions and vitamin D-related diseases which focused on understanding the mechanism of action of vitamin D in its many target cells.

Introduction
The history of vitamin D is a rich and storied subject and is now over 350 years old. It began in the early 1600s with the first descriptions of the human deficiency disease: rickets in children and osteomalacia in adults. Of course, there were no precise medical details that distinguished it from other bone diseases but treatises describing the symptoms and lithographs from that time showing bone deformities resembling rickets leave little doubt that it was vitamin D deficiency. It took another 250 years to define the cause of vitamin D deficiency in the 1900-1920 period when physicians and biochemists elucidated the role of sunlight and identified the chemical structure of the two main forms of the vitamin D molecule, vitamin D$_2$ and vitamin D$_3$. Another 50 years elapsed before the metabolism of vitamin D was first described in 1967 and the active form of vitamin D, namely 1,25-dihydroxyvitamin D (1,25-(OH)$_2$D) discovered. The period of time since has witnessed the exciting realization that vitamin D has its own set of dedicated specialized machinery consisting of transport proteins, metabolic enzymes and vitamin D receptor to mediate the actions of vitamin D, not only in bone, but in many other tissues around the body where it has a myriad of different physiological effects.

Before we get into the history of vitamin D, let us first remind the reader of the general aspects of its nomenclature, origins and principal functions. Vitamin D is a steroidal substance required by all vertebrates including humans to maintain blood calcium and phosphate within a narrow normal range and thereby support a healthy skeleton, muscle contraction, immune function and optimal cellular functions in many locations around the body [1]. The name vitamin D is a term coined by nutritionists, and is not a chemical term, which is defined as “a substance with anti-rachitic properties that will cure rickets”. In human biology, vitamin D usually refers to two substances: vitamin D$_3$ (usually known as cholecalciferol) of animal origin and vitamin D$_2$ (referred to as ergocalciferol) of plant or fungal origin. These two forms have roughly equal potencies, similar metabolic patterns and identical effects in the body.
Because of the four phases of vitamin D history, this review is divided into four sections each summarizing one particular time period:

1: 1650-1890: History of vitamin D Deficiency (Rickets)
2: 1890-1930: History of the discovery of vitamin D and its structural elucidation
3: 1930-1975: History of the discovery of vitamin D metabolites including 1,25-(OH)₂D₃

Since the different facets of the history of vitamin D represent interesting topics, and span many centuries, they have been reviewed by many previous historians, including the current author, and interested readers are invited to further access these because they focus on different aspects of the overall story [2-8].

1: 1650-1890: History of vitamin D Deficiency (Rickets)

There is no doubt that rickets was prevalent in Europe long before it was recognized as a specific disease in the 16th Century but the earliest documentation of the word “rickets” was in a domestic receipt book of an English family in 1632 and the earliest printed record of rickets as a disease causing death in the London Bill of Mortality in 1634 [reviewed by 2-4]. The term rickets is thought to have its origins in the verb in the Dorset dialect to “rucket”, which means to breathe with difficulty. However, some claim the term rickets is derived from the Anglo-Saxon word “wrikken”, meaning to twist. Rickets and osteomalacia were first clearly described by Daniel Whistler in the Netherlands (1645) as a condition in which the skeleton was poorly mineralized and deformed [9]. Francis Glisson (1650) provided the first documented records with his book entitled “De Rachitide” first published in Latin in 1650 and then translated into English in 1671 [10]. It features a lithograph of children with bowing of the legs and skeletal deformities which are the hallmarks of vitamin D deficiency. One of those Glisson lithographs was reproduced as a frontispiece in a landmark treatise on “Rickets including Osteomalacia and Tetany” by AF Hess in 1929 [11]. It is reproduced here as Figure 1.

A more recent definition of vitamin D deficiency has grown to include defective chondrocyte differentiation, lack of mineralization of the growth plate but the common feature of vitamin D deficiency is insufficiently mineralized or calcified bone matrix [1,12,13]. Rickets is characterized by a deformed and misshaped skeleton, particularly bending and bowing of the long bones and enlargement of the epiphyses of the joints of the rib cage, arms, legs and neck. Victims have painful movements of the rib cage and difficulty breathing. In China, medical texts refer to deformities of the rib cage in severe rickets as “chicken breast” [5]. Severe rickets is often accompanied by pneumonia. The loss of the important role of vitamin D in strengthening the immune system compounds this problem. Though rarely is rickets life-threatening, it certainly lowers the quality of life for the afflicted individual and leads to secondary problems. One of these secondary effects of rickets occurs in young women who had vitamin D deficiency in childhood causing deformities of the pelvis which result in difficulties in childbirth [14]. Sorter [14] speculates that rickets in early life must have resulted in numerous deaths of women during their first delivery.
Vitamin D deficiency is partly the result of inadequate skin synthesis of vitamin D$_3$ from 7-dehydrocholesterol compounded by a low dietary intake of vitamin D$_2$ from plant or fungal sources or vitamin D$_3$ from animal products. The advent of the Industrial Revolution in Western Europe heralded in massive air pollution in the form of smoke from mills and burning of fossil fuels. This dramatically reduced the amount of UV light reaching the ground. Since the workers needed for these new industrial jobs were required to move from their rural locations into dingy, poorly-lit cities, their exposure to UV light diminished and skin synthesis of vitamin D was reduced. Rickets resulted and was associated with lack of exposure to sufficient sunlight. Thus the 18th and 19th centuries saw a higher increase in rickets in the industrialized cities of northern Europe. The Dickensian character Tiny Tim, of the novel *A Christmas Carol*, clearly represents a child with a deformed skeleton who must have been a common sight in the dark cities of the late 19th century [7]. Rickets was particularly prevalent in the industrialized Britain of the 16th-20th centuries and thus it is no surprise that it was referred to in old texts as “the English disease” [7,15].

Despite the fact that rickets seemed to be associated with lack of exposure to sunlight, by the late 1700s some including Percival [16] in the UK were advocating the use of cod-liver oil for the treatment of rickets suggesting a nutritional aspect to vitamin D. In contrast, in the early 1800s Sniadecki [17] in Poland was documenting the differential incidence in city-dwellers and rural-dwellers suggesting some environmental factor was involved. He speculated that sunlight or fresh-air might be involved in the etiology of the disease. By the end of the 19th century, a rigorous debate roared on whether rickets was caused by the lack of some dietary substance or an environmental factor and how could these two points of view be reconciled.

2: 1890-1930: History of the discovery of vitamin D and its structural elucidation

By the 1890s some researchers such as Owen [18] and Palm [19], who clearly supported the environmental theory, produced evidence that there were big geographical differences in the incidence of rickets in different parts of the UK and northern and southern China. Palm, a medical missionary, went on to suggest that exposure of children to sunlight would cure rickets [19]. Subsequently, researchers in Europe and the USA namely Buchholtz (1904), Raczynski (1913), Huldshinsky (1919) and later Chick (1922) Hess and Weinstock (1924) performed experiments in which laboratory animals and children with rickets could be cured with sunlight or light from mercury arc lamps [7, 20-24]. This clearly demonstrated that lack of exposure to UV light was one cause of rickets.

But the proponents of the theory that a dietary factor could also be involved continued with their experiments too. The early 20th century was a momentous period in nutritional research in which nutritionists showed that a diet of highly purified carbohydrates, protein, fat and salt is unable to fully support growth and life of experimental animals [25]. By adding various “trace factors” researchers were able to restore growth and a full range of physiological actions. The first of these trace factors was thiamin discovered by Funk [26] which cured neuritis in what Funk termed the “vital amine or vitamin theory”. Thiamin was later renamed vitamin B$_1$ but it was one of a number of vitamin substances that are defined as “trace compounds which are derived from the diet and are required in small amounts per day and perform an essential role critical to life”. Vitamin D was identified as one of these substances playing a critical role in skeletal growth and calcium & phosphate homeostasis. However, strictly speaking vitamin D has been misnamed since
it can also be derived from exposure to UV light and is not required to be in the diet. In practise and for a variety of social and religious reasons, many populations around the world do not receive adequate UV light, especially during the winter months, so that a dietary intake is essential.

The discovery of the nutritional factor, later termed vitamin D by McCollum [27], came largely as the result of the work of a number of researchers: Mellanby, McCollum, Steenbock and Hart working independently. Sir Edward Mellanby [28] in the UK reasoned that rickets might be due to a dietary deficiency and managed to produce beagle dogs with severe rickets by feeding them oatmeal and then cured their rickets with cod-liver oil. Since cod-liver oil is a mixture of lipids and a rich source of vitamin A, it was not clear what the active ingredient might be. McCollum [29], working firstly at the U Wisconsin and then Johns-Hopkins, heated & bubbled oxygen through the cod-liver oil to destroy the vitamin A and found that the product still cured rickets. Building on the new vitamin nomenclature, he termed the new substance vitamin D. But how was the field to reconcile the apparently unconnected findings that UV light and a nutritional substance termed vitamin D could both cure rickets? Harry Steenbock also working at the U Wisconsin-Madison performed the definitive experiment. Steenbock and Black experimented with the diets of goats and found that sunlight or UV irradiation of the animals or their diets resulted in rickets being cured in the goats [30]. Steenbock traced the bioactive substance in irradiated food to the non-saponifiable fraction of lipids in the diet and showed that it cured rickets [31]. Dietary vitamin D was born.

Subsequently, Steenbock was able to show that irradiated yeast contained significant amounts of vitamin D, later shown to be vitamin D$_2$; and that the yeast could be irradiated and added to milk which formed the basis of the first food fortification with vitamin D [5]. Though, Steenbock and the University of Wisconsin filed a patent for milk fortification with vitamin D, the proceeds from this discovery were used to establish the Wisconsin Alumni Research Foundation (WARF) which was one of the prototypical organizations intended to allow universities to plough the benefits their research into future research. WARF funded the research of a number of scientists inside and outside of the vitamin D field, included several Nobel laureates, with the proceeds of Steenbock’s patent. Furthermore, vitamin D fortification of a variety of foodstuffs (including milk, margarine, bread and even beer) has become a major nutritional tool in the fight to prevent rickets and osteomalacia around the world [5].

In the late 1920s, Windaus and his colleagues [32] isolated the key anti-rachitic substance from a mixture of irradiated plant sterols and named it vitamin D$_1$, although they did not identify its structure. Later vitamin D$_1$ was shown to be a mixture of vitamin D$_2$ and tachysterol. A British group headed by Askew [33] successfully identified and determined the structure of the anti-rachitic, plant-derived sterol as vitamin D$_2$ or ergocalciferol. Windaus’s group confirmed the structure of vitamin D$_2$ [34] and also isolated and identified the animal-derived, anti-rachitic vitamin D$_3$ or cholecalciferol and its skin precursor, 7-dehydrocholesterol [35]. For his discovery of the structures of vitamin D$_3$, 7-dehydrocholesterol and several other sterols, Adolf Windaus was awarded the 1928 Nobel Prize for Chemistry. (Figure 2)
Chemically synthesized vitamin D$_2$ and vitamin D$_3$ have been available since the 1930s and paved the way for the study of their biological functions and metabolism. The physiological roles of vitamin D are primarily its roles in calcium and phosphate homeostasis [1] and include:

1) Stimulation of intestinal calcium and phosphate absorption
2) Mobilization of calcium from bone
3) Renal reabsorption of calcium

All three of these functions serve to raise blood calcium and phosphate and ensure that these ions are available to ensure health and prevent rickets. Elucidating the details of these physiological functions became the main foci during the 1930-1960 time period and research revealed that vitamin D was intimately connected to the roles of other calcium and phosphate-related hormones including parathyroid hormone (PTH) and calcitonin. Details of these connections are beyond the scope of this chapter and are described in reviews [e.g. 1] and in other articles in this Special Issue.

In the 1960s, there was considerable debate over whether the functions of vitamin D were carried out by vitamin D itself or its possible metabolites. Consequently, intense effort was put into studying the metabolism of vitamin D by using chemically-synthesized radioactive versions of vitamin D$_2$ and vitamin D$_3$. The pioneer in this area was Egon Kodicek at the Dunn Nutritional Laboratories, U Cambridge UK. After 10 years of work, Kodicek [36] concluded that vitamin D was active without being metabolized. In retrospect, the radioactive vitamin D his group were using was insufficiently labeled to detect its metabolites. However, Hector DeLuca, again at the U Wisconsin-Madison, and the final graduate student of Harry Steenbock, synthesized radioactive vitamin D$_3$ with much higher specific activity [37] and was able to demonstrate metabolism to more polar metabolites, the principal one being 25-hydroxyvitamin D$_3$ (25-OH-D$_3$) [38] made in the liver and the first identified natural vitamin D metabolite.

25-OH-D$_3$ proved to be more potent biologically than vitamin D$_3$ and was present in the bloodstream at a higher concentration [38]. We now identify 25-OH-D$_3$ as the principal circulating form of vitamin D. But that is not the extent of vitamin D metabolism. Several other groups then entered or re-entered the picture, including Dr Kodicek’s, as well as that of one of Dr DeLuca’s former graduate students Dr Anthony Norman. Amongst the other polar products of vitamin D$_3$ was a metabolite even more potent than 25-OH-D$_3$, namely 1$\alpha$,25-dihydroxyvitamin D$_3$ (1,25-(OH)$_2$D$_3$) which is now universally accepted as the hormonal form of vitamin D$_3$. Several groups including Dr Kodicek’s [39] Dr Norman’s [40] and Dr DeLuca’s [41] were credited with playing a role in the discovery and/or in the structural identification of 1,25-(OH)$_2$D$_3$. Kodicek’s group administered a mixture of radioactive [4-$^{14}$C] & [1-$^3$H]vitamin D$_3$ preparations and showed that one polar metabolite lost its tritium atom during metabolism that aided in its identification as a 1$\alpha$-hydroxylated compound [39]. Furthermore, the Cambridge group also showed that the hormone was biologically generated in the kidney [39,42]. Dr Norman’s group showed that the new metabolite was associated with the chromatin of intestinal mucosal cells and had greater biological activity than even 25-OH-D$_3$ [40]. Holick et al [41] showed that the additional 1-hydroxyl group was in the 1$\alpha$- orientation and supported their identification of the metabolite as 1$\alpha$,25-(OH)$_2$D$_3$ with mass spectrometry. Chemically synthesized 1,25-(OH)$_2$D$_3$ was first produced by Semmler et al [43] and made commercially by a group headed by Dr Milan Uskokovic at Hoffmann-La Roche in the early 1970s and is known clinically by the name calcitriol [44].
The identification of the principal metabolites: 25-OH-D$_3$ and 1,25-(OH)$_2$D$_3$ spawned a 
fenzy of research activity in the vitamin D area and the discovery of a number of other vitamin D 
metabolites [1]. Amongst these are the principal metabolites of vitamin D$_2$ including 25-OH-D$_2$
[45], 1,25-(OH)$_2$D$_2$ [46] and 24,25-(OH)$_2$D$_2$ [47]. Also identified in that mixture of metabolites 
arising from radioactive vitamin D$_3$ were several compounds that are presumed to be inactive 
catabolites including: 24,25-(OH)$_2$D$_3$, 25,26-(OH)$_2$D$_3$, 25-OH-D$_3$-26,23-lactone, 1,24,25-(OH)$_3$D$_3$
and calcitroic acid. [48-53] A summary of the main metabolites of both vitamin D$_3$ and vitamin 
D$_2$ along with their tissue source, biosynthetic enzyme, details of first reporting and biological role 
is presented in Table 1 and depicted in a metabolic pathway diagram (Figure 3).

4: 1975-Present: History of the discovery of the vitamin D cellular machinery, functions and 
vitamin D-related human diseases.

The discovery of the active forms of vitamin D heralded in a search for:

a) the signal transduction mechanisms to explain how 1,25-(OH)$_2$D$_3$ was able to produce its 
various biological effects;

b) identification of the enzymes responsible for the synthesis and catabolism of 1,25-(OH)$_2$D$_3$;

c) a clear understanding of the regulation of the vitamin D endocrine system

These studies began almost as soon as metabolism was recognized in the late 1960s when Mark 
Haussler, in AW Norman’s laboratory, demonstrated that vitamin D metabolites associated with 
the chromatin [54]. Clear evidence of the protein that is now termed, the vitamin D receptor (VDR) 
was produced by Haussler’s lab [55]. The VDR protein from various species was later purified 
and its gene cloned by Haussler’s group [56,57]. Study of the pure protein has led to a 
determination of its crystal structure [58]. Parallel to these investigations of the VDR have come 
other studies on how it works both at the whole-body level in calcium and phosphate homeostasis 
and other pleiotropic functions [1,8,59] and at the cellular level in a classic steroid hormone super-
family like process through a transcriptional mechanism [60]. Over the past 30 years, Mark 
Haussler, Wes Pike & colleagues [61] have demonstrated that 1,25-(OH)$_2$D$_3$ works through a 
VDR-mediated mechanism that involves many coactivators and repressors to directly interact with 
and regulate hundreds of genes around the body. Other researchers, most notably Anthony Norman 
[62], have proposed that some of the actions of vitamin D occur through rapid non-genomic 
signaling pathways, possibly involving a plasma membrane vitamin D receptor but this protein has 
ever been fully characterised at the molecular level. Nevertheless, there remains some uncertainty 
that all vitamin D ligands and analogs produce their effects through a genomic VDR mechanism 
[63].

The history of two other components of the vitamin D machinery deserve some mention. 
These are vitamin D-binding globulin [64,65] and the cytochromes P450-containing enzymes that 
metabolize vitamin D into its many metabolites [66]. Being a fat-soluble vitamin, Vitamin D 
requires a protein to transport it around the body and the vitamin D-binding globulin (usually 
abbreviated as DBP) performs this function. DBP was first identified as Gc (group specific 
component) in the 1970s and its properties have been reviewed extensively by the father figure of 
the field Roger Bouillon, U Leuven, Belgium [65]. DBP has a high affinity for most of the main 
metabolites of vitamin D, most notably 25-OH-D, and because of this 25-OH-D is the main 
circulating form in the blood.
The cytochrome P450-containing enzymes (CYPs) responsible for vitamin D metabolism were first studied in the early 1970s in tissue extracts of liver and kidney [67,68,69]; then in tissue culture and given names based upon their hydroxylation activity: 25-hydroxylase, 1α-hydroxylase and 24-hydroxylase. In the early 1990-2005 period all three enzymes were purified, cloned and expressed in cell culture systems, principally by Canadian group of St-Arnaud [70] as well as the Japanese groups of Kato S [71], Okuda [72] and Sakaki [73,74] as well as Russell’s group at the U Texas [75]. The 3 enzymes are now known as CYP2R1, CYP27B1 and CYP24A1. A review of the CYP field and how these enzymes operate & how they are regulated is provided [66]. A summary of the history of the signal transduction protein machinery for vitamin D including VDR, DBP and the various CYPs is provided in Table 2.

No review of the recent history of vitamin D would be complete without an overview of how defects in vitamin D metabolism result in human disease. It is now evident that vitamin D deficiency and rickets are caused by several genetic and acquired errors in vitamin D metabolism which involve any of the major protein components of the vitamin D machinery described above. These are compiled into Table 3 where we document the disease name, the component of the vitamin D machinery affected, as well as the publication first describing it. Besides diseases involving too little 1,25-(OH)₂D₃ and resulting in rickets, diseases involving too much 1,25-(OH)₂D₃ which cause hypercalcemia are also included in Table 3. Most of these diseases involving a shortage of 1,25-(OH)₂D₃ are now treated with vitamin D analogs which were developed from knowledge of the metabolism and biological actions of vitamin D. Currently approved and marketed vitamin D analogs are listed in Table 4 along with their original publications.

Conclusions
The history of vitamin D is indeed a rich subject which has already stretched over 350 years and involved the 4 phases described in this review. While the chemical entity, vitamin D remained unknown for all but 100 of those years, the significant medical consequences of vitamin D deficiency were evident for the whole of that time. Many physicians, nutritionists, biochemists, chemists and molecular biologists have worked to elucidate our current knowledge of the nature of vitamin D in addition to its metabolism, mechanism of action and biological activities. That knowledge has paid dividends by providing new therapies for the treatment of deficiency and excess vitamin D action. The field of vitamin D research is arguably one of the highlights of modern medicine.

Acknowledgements
This review is dedicated to Emeritus Professor Hector F. DeLuca, Department of Biochemistry, University of Wisconsin-Madison, who pioneered the renaissance period in the vitamin D field in 1967 with the discovery of the first vitamin D metabolite, 25-OH-D₃. Dr DeLuca spawned a revolution which led to a clear understanding of how vitamin D works in calcium and phosphate homeostasis and led to a series of vitamin D analogs that can be used to treat diseases involving dysfunctional vitamin D metabolism. The author joined the DeLuca laboratory in 1972, and as a result he had the opportunity to meet, collaborate with, and celebrate many of the main players cited in this historical review. The author thanks them all for their important contributions.
Declaration of interest

The author has no conflicts of interest to declare that could be perceived as prejudicing the impartiality of the review.

Funding

This review did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

References

7. Chesney RW. Theobald Palm and his remarkable observation: how the sunshine vitamin came to be recognized. *Nutrients* 2012 4 42–51.
16. Percival T. Essays Medical, Philosophical and Experimental on the Medical Use of Cod-liver Oil, 1789 2 London.


37. Neville PF & DeLuca HF. The synthesis of [1,2-3H]vitamin D3 and the tissue localization of a 0.25 µg (10 IU) dose per rat. *Biochemistry* 1966 5 2201-2207.


59. DeLuca HF & Zierold C. Mechanisms and functions of vitamin D. *Nutritional Reviews* 1998 **56** S 4-10.


64. Daiger SP, Schanfield MS & Cavalli-Sforza LL. Group-specific component (Gc) proteins bind vitamin D and 25-hydroxyvitamin D. *Proceedings of the National Academy Sciences USA* 1975 **72** 2076-2080.


75. Cheng JB, Levine MA, Bell NH, Mangelsdorf DJ & Russell DW. Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proceedings of the National Academy Sciences U S A. 2004 101 7711-7715.


86. Zhu JG, Ochalek JT, Kaufmann M, Jones G & DeLuca HF. CYP2R1 is a major, but not exclusive, contributor to 25-hydroxyvitamin D production in vivo. Proceedings of the National Academy of Sciences USA 2013 110 15650-15655.


100. Lam HY, Schnoes HK & DeLuca HF. 1α-Hydroxyvitamin D2: a potent synthetic analog of vitamin D2. Science 1974 186 1038-1040.


Figure Legends

Figure 2: Structures of Vitamin D<sub>2</sub> and D<sub>3</sub>. The two versions of vitamin D differ only in their side chains vitamin D<sub>2</sub> possessing an additional C-22-23 double bond and a C-24 methyl group. The modifications make little significant difference in their metabolism or biological actions.

Figure 3: Metabolism and Mechanism of Action of Vitamin D<sub>3</sub>. Skin synthesized or dietary vitamin D<sub>3</sub> is converted via a two-step hydroxylation process into the active hormonal form 1,25-(OH)<sub>2</sub>D<sub>3</sub>. The hormone binds to the vitamin D receptor (VDR) and regulates serum calcium (sCa<sup>2+</sup>) and serum phosphate (sPO<sub>4</sub>) levels ensuring sufficient minerals for normal cellular activity around the body including bone. Insufficient vitamin D results in insufficient 1,25-(OH)<sub>2</sub>D<sub>3</sub> and vitamin deficiency rickets. Circled in red are the proteins in the vitamin D-specific machinery that when mutated also result in some type of rickets. Circled in blue is the enzyme CYP24A1 that when mutated results in elevated 1,25-(OH)<sub>2</sub>D<sub>3</sub> and hypercalcemia and/or kidney stones.
Table 1: History of the Discovery of the major metabolites of Vitamins D$_2$ and D$_3$

<table>
<thead>
<tr>
<th>Metabolite</th>
<th>Tissue Source</th>
<th>Biosynthetic Enzyme</th>
<th>Biological Role</th>
<th>Discovery</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Vitamin D$_3$ Metabolites</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25-OH-D$_3$</td>
<td>Liver</td>
<td>25-Hydroxylase (CYP2R1)</td>
<td>Main Circulating Metabolite</td>
<td>Blunt et al, 1968 [38]</td>
</tr>
<tr>
<td>1,25-(OH)$_2$D$_3$</td>
<td>Kidney (major)</td>
<td>1α-Hydroxylase (CYP27B1)</td>
<td>Active Hormonal Form</td>
<td>Lawson et al, 1969 [39]</td>
</tr>
<tr>
<td></td>
<td>Extra-renal sites</td>
<td></td>
<td></td>
<td>Myrtle et al, 1970 [40]</td>
</tr>
<tr>
<td>24,25-(OH)$_2$D$_3$</td>
<td>Kidney (major)</td>
<td>24-Hydroxylase (CYP24A1)</td>
<td>Principal Catabolite</td>
<td>Suda et al, 1970a [48]</td>
</tr>
<tr>
<td></td>
<td>Extra-renal sites</td>
<td></td>
<td></td>
<td>Holick et al, 1972 [49]</td>
</tr>
<tr>
<td>25,26-(OH)$_2$D$_3$</td>
<td>Unknown</td>
<td>26-Hydroxylase (?)</td>
<td>Catabolite</td>
<td>Suda et al 1970b [50]</td>
</tr>
<tr>
<td></td>
<td>Extra-renal sites</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1,24,25-(OH)$_3$D$_3$</td>
<td>Kidney (major)</td>
<td>24-Hydroxylase (CYP24A1)</td>
<td>Unknown Possible catabolite</td>
<td>Holick et al, 1974 [52]</td>
</tr>
<tr>
<td></td>
<td>Extra-renal sites</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calcitroic Acid</td>
<td>Kidney (major)</td>
<td>24-Hydroxylase (CYP24A1)</td>
<td>Excretory Form</td>
<td>Esvelt et al, 1981[53]</td>
</tr>
<tr>
<td></td>
<td>Extra-renal sites</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calcioc Acid</td>
<td>Kidney (major)</td>
<td>24-Hydroxylase (CYP24A1)</td>
<td>Excretory Form</td>
<td>Kaufmann et al 2019 [76]</td>
</tr>
<tr>
<td></td>
<td>Extra-renal sites</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4α,25-(OH)$_2$D$_3$</td>
<td>Liver</td>
<td>General Cytochrome P450</td>
<td>Excretory Form</td>
<td>Wang et al 2013 [77]</td>
</tr>
<tr>
<td>4β,25-(OH)$_2$D$_3$</td>
<td></td>
<td>(CYP3A4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Vitamin D$_2$ Metabolites</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25-OH-D$_2$</td>
<td>Liver</td>
<td>25-Hydroxylase (CYP2R1)</td>
<td>Main Circulating Metabolite</td>
<td>Suda et al 1969 [45]</td>
</tr>
<tr>
<td>1,25-(OH)$_2$D$_2$</td>
<td>Kidney (major)</td>
<td>1α-Hydroxylase (CYP27B1)</td>
<td>Active Hormonal Form</td>
<td>Jones et al 1975 [46]</td>
</tr>
<tr>
<td>24,25-(OH)$_2$D$_2$</td>
<td>Kidney (major)</td>
<td>24-Hydroxylase (CYP24A1)</td>
<td>Principal Catabolite</td>
<td>Jones et al 1980 [47]</td>
</tr>
<tr>
<td>1,24,25-(OH)$_3$D$_2$</td>
<td>Kidney (major)</td>
<td>24-Hydroxylase (CYP24A1)</td>
<td>Presumed Catabolite</td>
<td>Reddy et al 1986 [78]</td>
</tr>
</tbody>
</table>

Copyright © 2022 the authors
<table>
<thead>
<tr>
<th>Protein</th>
<th>Abbreviation</th>
<th>Tissue Location or Source</th>
<th>Biological Function</th>
<th>Discovery</th>
<th>Gene Cloning</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitamin D Receptor</td>
<td>VDR</td>
<td>Most tissues except liver</td>
<td>Regulation of vitamin D-dependent genes</td>
<td>Haussler [1969] [80]</td>
<td>McDonnell et al 1987[56]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Brumbaugh et al 1975[55]</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Takeyama et al 1997[71]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(and 23- &amp; 26-hydroxylation)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*The specific vitamin D signal transduction machinery is specialized to transport, activate, mediate the biological effects of & catabolize vitamin D. Other cellular proteins play a general role in vitamin D metabolism and action e.g. CYP3A4 but this degrades many other molecules and drugs.*
<table>
<thead>
<tr>
<th>Disease</th>
<th>Cause</th>
<th>Initial Report</th>
<th>Animal Model equivalent</th>
<th>Generated by</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitamin D Deficiency Rickets</td>
<td>Lack of dietary vitamin D</td>
<td>F Glisson 1671[10]</td>
<td>Beagle dog on oatmeal diet</td>
<td>Mellanby, 1919 [28]</td>
</tr>
<tr>
<td></td>
<td>Lack of skin synthesis of D</td>
<td></td>
<td>Lactating Goat Model</td>
<td>Steenbock &amp; Black, 1924[30]</td>
</tr>
<tr>
<td>Type 1A</td>
<td></td>
<td></td>
<td></td>
<td>Panda et al 2001[84]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>St-Arnaud R et al 2003[85]</td>
</tr>
<tr>
<td>Vitamin D Dependency Rickets</td>
<td>Genetic defect in CYP2R1</td>
<td>Cheng et al 2004 [75]</td>
<td>CYP2R1 null mouse</td>
<td>Zhu et al 2013[86]</td>
</tr>
<tr>
<td>Type 1B</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type 2</td>
<td></td>
<td>Eil et al 1981[88]</td>
<td></td>
<td>Li Y-C et al 1998[90]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Schlingmann et al 2011[92]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Brickman et al 1974[95]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Table 4: History of the Commercially Approved Vitamin D Drugs (Vitamin D analogs) used to treat Rickets and related diseases**

<table>
<thead>
<tr>
<th>Vitamin D Analog</th>
<th>Drug name</th>
<th>Marketed by</th>
<th>Field of Use*</th>
<th>Initial Report</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>25-OH-D&lt;sub&gt;3&lt;/sub&gt;</td>
<td>Calderol</td>
<td>Organon</td>
<td>Vitamin Deficiency</td>
<td>Blunt &amp; DeLuca 1969[97]</td>
<td>First vitamin D metabolite</td>
</tr>
<tr>
<td>Rayaldee</td>
<td>OPKO Renal</td>
<td></td>
<td>Chronic kidney Disease</td>
<td></td>
<td>Licensed by Upjohn, Kalamazoo</td>
</tr>
<tr>
<td>1,25-(OH)&lt;sub&gt;2&lt;/sub&gt;D&lt;sub&gt;3&lt;/sub&gt;</td>
<td>Calcijex</td>
<td>Roche</td>
<td>Vitamin D Dependency Type 1A</td>
<td>Semmler et al 1972[43]</td>
<td>First vitamin D active analog</td>
</tr>
<tr>
<td>Generic</td>
<td></td>
<td></td>
<td>Chronic Kidney Disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1α-OH-D&lt;sub&gt;3&lt;/sub&gt;</td>
<td>One-alpha</td>
<td>Leo Pharma</td>
<td>Vitamin D Deficiency</td>
<td>Holick et al 1973[98]</td>
<td>1-hydroxylated prodrug</td>
</tr>
<tr>
<td>Alfacalcidiol</td>
<td></td>
<td></td>
<td>Chronic Kidney Disease</td>
<td>Barton et al 1973[99]</td>
<td>not requiring activation by kidney</td>
</tr>
<tr>
<td>1α-OH-D&lt;sub&gt;2&lt;/sub&gt;</td>
<td>Hectorol</td>
<td>Genzyme/Sanofi</td>
<td>Chronic Kidney Disease</td>
<td>Lam et al 1974[100]</td>
<td>1-hydroxylated prodrug</td>
</tr>
<tr>
<td>Doxercalciferol</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>not requiring activation by kidney</td>
</tr>
<tr>
<td>Calcipotriol</td>
<td>Daivonex</td>
<td>Leo Pharma</td>
<td>Psoriasis</td>
<td>Calverley 1987 [102]</td>
<td>Topical rapidly-metabolized side-chain modified vitamin D analog</td>
</tr>
</tbody>
</table>

*Many of the vitamin D drugs used in Chronic Kidney Disease Stages 3-4 and beyond are used to suppress secondary hyperparathyroidism, as well as having a moderate serum calcium-raising activity.*
Figure 1:
Lithograph from Glisson’s “de Rachitide”

Reproduced from the US National Library digital collection.
Figure 2: Structures of Vitamin D$_2$ and D$_3$
Figure 3: Metabolism and Mechanism of Action of Vitamin D₃

DEFECTIVE VITAMIN D METABOLISM or DEFECTIVE RESPONSE TO HORMONE

RICKETS or HYPERCALCEMIA/RENAL STONES